Table 2.
Sensitivity analysis of Mendelian randomization studies of polyunsaturated fatty acids and different body parts.
| Traits (Outcome) | Fatty acids (Exposure) | Heterogeneity test | MR-Egger pleiotropy test | MR-PRESSO | F statistics | ||
|---|---|---|---|---|---|---|---|
| p-value | |||||||
| Q-value | p-value | Intercept | p-value | ||||
| Atypical facial pain | Omega-3 FAs | 42.665 | 0.613 | −0.012 | 0.391 | 0.637 | 264.64 |
| Omega-6 FAs | 50.003 | 0.433 | 0.013 | 0.511 | 0.385 | 123.56 | |
| Linoleic Acid | 41.797 | 0.480 | 0.015 | 0.507 | 0.475 | 129.93 | |
| DHA RO63 | 40.887 30.124 | 0.476 0.611 | −0.011 0.018 | 0.487 0.284 | 0.561 0.655 | 210.76336.64 | |
| Pain in throat and chest | Omega-3 FAs | 60.663 | 0.048 | −0.002 | 0.454 | 0.066 | 264.54 |
| Omega-6 FAs | 52.953 | 0.224 | −0.004 | 0.356 | 0.255 | 118.22 | |
| Linoleic Acid | 41.770 | 0.234 | −0.0003 | 0.952 | 0.246 | 118.17 | |
| DHA RO63 | 59.616 50.852 | 0.030 0.024 | −0.004 0.002 | 0.277 0.692 | 0.051 0.085 | 210.89338.73 | |
| Abdominal and pelvic pain | Omega-3 FAs | 66.439 | 0.026 | 0.002 | 0.538 | 0.05 | 267.12 |
| Omega-6 FAs | 56.939 | 0.177 | 0.003 | 0.354 | 0.179 | 125.39 | |
| Linoleic Acid | 53.823 | 0.046 | 0.008 | 0.084 | 0.061 | 110.86 | |
| DHA RO63 | 50.547 46.758 | 0.146 0.057 | 0.002–0.002 | 0.415 0.404 | 0.2 0.136 | 210.95338.81 | |
| Lower back pain or/and sciatica | Omega-3 FAs | 37.939 | 0.795 | −0.004 | 0.126 | 0.805 | 264.39 |
| Omega-6 FAs | 47.124 | 0.549 | −0.001 | 0.861 | 0.621 | 123.48 | |
| Linoleic Acid | 40.128 | 0.553 | −0.003 | 0.469 | 0.682 | 129.86 | |
| DHA RO63 | 46.656 33.791 | 0.251 0.429 | 0.0003 0.004 | 0.933 0.829 | 0.306 0.496 | 209.51336.41 | |
| Pain in joint | Omega-3 FAs | 54.863 | 0.173 | 0.002 | 0.530 | 0.201 | 270.57 |
| Omega-6 FAs | 54.434 | 0.275 | 0.002 | 0.637 | 0.366 | 125.38 | |
| Linoleic Acid | 47.913 | 0.245 | 0.003 | 0.611 | 0.366 | 131.66 | |
| DHA RO63 | 50.414 54.827 | 0.1490.009 | 0.004–0.0003 | 0.297 0.959 | 0.208 0.06 | 212.76341.84 | |
| Pain in limb | Omega-3 FAs | 63.067 | 0.048 | −0.008 | 0.071 | 0.066 | 266.62 |
| Omega-6 FAs | 57.535 | 0.100 | −0.006 | 0.343 | 0.102 | 129.32 | |
| Linoleic Acid | 55.155 | 0.056 | −0.005 | 0.441 | 0.058 | 133.56 | |
| DHA RO63 | 44.484 28.356 | 0.327 0.446 | −0.002 0.008 | 0.671 0.083 | 0.38 0.482 | 210.69363.87 | |
| Low back pain | Omega-3 FAs | 43.202 | 0.590 | −0.002 | 0.491 | 0.575 | 266.87 |
| Omega-6 FAs | 49.298 | 0.461 | 0.002 | 0.620 | 0.519 | 124.25 | |
| Linoleic Acid | 46.868 | 0.280 | −0.002 | 0.730 | 0.438 | 130.59 | |
| DHA RO63 | 42.586 33.900 | 0.403 0.424 | 0.002 0.004 | 0.490 0.822 | 0.412 0.416 | 210.82338.60 | |
| Gynecological related pain | Omega-3 FAs | 54.807 | 0.175 | −0.008 | 0.297 | 0.234 | 288.78 |
| Omega-6 FAs | 56.404 | 0.218 | −0.018 | 0.080 | 0.146 | 130.77 | |
| Linoleic Acid | 51.101 | 0.158 | −0.018 | 0.136 | 0.15 | 143.53 | |
| DHA RO63 | 44.903 39.586 | 0.312 0.200 | −0.009 0.009 | 0.271 0.666 | 0.382 0.311 | 222.02357.52 | |
DHA, Docosahexaenoic acid; RO63, ratio of omega-6 FAs to omega-3 FAs; Gynecological related pain, pain and other conditions associated with female genital organs and menstrual cycle; p < 0.05 is set as the significant threshold. p < 0.05 was considered statistically significant.